Home Blog Page 2593

Maha Shivratri 2026: Must-Visit Ghats In Varanasi

0
Maha Shivratri 2026: Must-Visit Ghats In Varanasi

Infosys Rolls Out 85% Average Performance Bonus In Q3FY26, Best In Over 3 Years

0
Infosys Seeks Home Electricity Details From Work-From-Home Staff; Here's Why

Last Updated:

Over recent quarters, payouts had gradually improved from roughly 65 percent to 80 percent and now to an average of about 85 percent in Q3FY26.

Infosys logo is seen.

Infosys logo is seen.

IT major Infosys rolled out performance bonus payouts averaging around 85 percent for the quarter ended December 31, 2025 (Q3FY26), marking the strongest variable pay outcome for eligible employees in at least the past three-and-a-half years, Moneycontrol reported citing people in the know.

The bonus payout for mid- to junior-level employees ranges between 75 percent and 100 percent, with most employees clustering around the organisation-wide average of 85 percent, the report said. The development signals a steady recovery in variable compensation at the Bengaluru-headquartered IT services firm. Over recent quarters, payouts had gradually improved from roughly 65 percent to 80 percent and now to an average of about 85 percent in Q3FY26.

Employees are expected to receive their bonus letters over the next few days, with the payout scheduled to be credited along with their February salary.

One employee told the outlet that it is the strongest bonus outcome seen in recent years. The payout is also among the rare instances since the Covid-19 period when variable pay has approached the upper end of the eligible range.

Infosys last paid out 100 percent variable compensation during the pandemic. In the quarters that followed, payouts were lower amid macroeconomic uncertainty and a broader slowdown in client spending across global markets.

The higher payout comes at a time when global IT stocks have faced renewed pressure, driven by concerns over rapid advances in artificial intelligence and their potential impact on traditional IT services models.

Shares of global IT firms have seen sharp sell-offs in recent weeks amid heightened investor focus on AI leaders such as Anthropic. Investors fear that generative AI tools could compress pricing, automate routine services work and reduce demand for legacy outsourcing models.

Against that backdrop, the improved bonus payout at Infosys is being viewed as a signal of operational resilience and near-term performance strength, even as sentiment around the broader IT sector remains cautious.

Click here to add News18 as your preferred news source on Google.

Follow News18 on Google. Join the fun, play games on News18. Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the News18 App to stay updated.
News business markets Infosys Rolls Out 85% Average Performance Bonus In Q3FY26, Best In Over 3 Years
Disclaimer: Comments reflect users’ views, not News18’s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Read More

Consumer prices rose 2.4% annually in January, less than expected

0
Consumer prices rose 2.4% annually in January, less than expected

The cost of goods and services rose at a slower annual rate than expected in January, providing hope that the nagging U.S. inflation problem could be starting to ease.

The consumer price index for January accelerated 2.4% from the same time a year ago, down 0.3 percentage point from the prior month, the Bureau of Labor Statistics reported Friday. That pulled the inflation rate down to where it was the month after President Donald Trump in April 2025 announced aggressive tariffs on U.S. imports.

Excluding food and energy, the core CPI was up 2.5%, the lowest level since April 2021. Economists surveyed by Dow Jones had been looking for an annual rate of 2.5% for both readings.

On a monthly basis, the all-items index was up a seasonally adjusted 0.2% while core gained 0.3%. The forecast had been 0.3% for both.

Though the category accounted for much of the CPI gain, shelter costs rose just 0.2% for the month, bringing the annual increase down to 3%. Shelter makes up more than one-third of the CPI.

Elsewhere, food prices increased 0.2% as five of the six major grocery group categories posted gains. Energy fell 1.5% while vehicle prices also were muted, with new vehicles up just 0.1% and used cars and trucks falling 1.8%. Airline fares jumped 6.5% while egg prices fell 7% and are now down 34% over the past year after a meteoric surge.

Stock market futures were little changed after the report while Treasury yields moved lower.

“This is great news on inflation,” said Heather Long, chief economist at Navy Federal Credit Union. “Inflation fell to the lowest level since May and key items such as food, gas and rent are cooling off. This will provide much needed relief for middle class and moderate-income families.”

The lower-than-expected reading helped boost the outlook for Federal Reserve interest rate cuts in the futures market. Traders raised the odds for a reduction in June to about 83%, according to the CME Group’s FedWatch tool.

The report adds to a mixed economic picture.

At the macro level, the U.S. shrugged off a slow start in 2025 and has been barreling forward since, with fourth-quarter growth pegged at 3.7%, according to the latest update from the Atlanta Fed’s GDPNow, a running tracker of incoming data.

But inflation has continued to hold above the Fed’s 2% annual target even with generally contained energy prices. Moreover, Fed officials continue to express concern about the labor market, which added only 15,000 jobs a month last year. Consumer spending held up fairly well last year, though it was unexpectedly flat heading into the holiday season.

Economists had expected Trump’s tariffs to spark inflation, but the impact has been largely tilted toward select goods rather than a broader impact.

“The tariffs have had a clear impact on products such as furniture and appliances, but the key items in many family budgets are cooling off,” Long added.

With the conflicting economic signals, the Fed is widely expected to stay on hold until June after a rate-cutting cycle that saw three reductions in the latter part of 2025. The central bank faces shifting dynamics this year, with a rotating cast of regional presidents that seems titled toward a more aggressive posture on fighting inflation and a chair-designate, Kevin Warsh, who is likely to push for lower rates.

Treasury Secretary Scott Bessent on Friday told CNBC that he sees an “investment boom” acting as a tailwind while inflation gets back to the Fed’s target “in the middle of this year.”

“We’ve got to get away from this idea that growth automatically has to be tampered down, because growth, per se, is not inflationary.” Bessent added. “It’s growth that leaks into areas where there’s not sufficient supply, and everything this administration is doing is creating more supply.”

The January inflation report was delayed a few days because of the partial government shutdown.

The Fed does not use the CPI as its primary inflation measure. Instead, it more closely watches the Commerce Department’s personal consumption expenditures price index, the December reading of which will be released Feb. 20.

Hailey Bieber turns heads just hours after major business win

0
Hailey Bieber turns heads just hours after major business win

Hailey Bieber has turned heads with her stunning red carpet look in Sydney.

Just hours after the launch of her skincare brand in Australia, the Rhode founder stunned everyone at the premiere of Wuthering Heights.

The wife of Justin Bieber made appearance in sheer black Chantilly lace gown by Saint Laurent, featuring a plunging neckline, halter-style bralette, and flowing hemline.

For her look, Hailey paired it with minimal jewelry and completed it with strappy black sandals.

It is pertinent to mention that earlier in the day, Hailey Bieber celebrated the launch of her beauty brand Rhode in Australia at popular retailer Mecca.

Speaking to Vogue Australia, Hailey expressed her excitement over the warm reception. She said, “Expanding Rhode into new markets is always exciting, and the response has been overwhelmingly positive. I’ve always imagined Rhode on shelves around the world, and bringing it to Australia and New Zealand feels like a major milestone in our journey.”

Adding, “Seeing the excitement from our community here over the years has meant so much to me, and it’s been amazing to feel the buzz here. Finally being able to share Rhode with our community here is a really special moment for us all.”

On personal front, Hailey Bieber is mother to son Jack Blues Bieber, whom she shares with husband Justin Bieber.

Can TrumpRx help you save money on drugs? Here’s what experts say.

0
Can TrumpRx help you save money on drugs? Here's what experts say.

After last week’s launch of TrumpRx, President Trump described the discounted drug platform as “one of the most transformative health care initiatives of all time.” But experts and health care advocates said that limitations with the new service could undermine its value to consumers.

“The prices are absolutely cheaper than list prices, but only for cash patients or patients whose insurance does not sufficiently cover these drugs,” Yunan Ji, a health policy expert at Georgetown’s McDonough School of Business, told CBS News. “For a small share of the market, it will deliver meaningful savings, but it is not going to change the whole drug pricing landscape for most Americans.”

Anthony Wright, executive director of Families USA, an advocacy group for health care consumers, applauded the Trump administration’s effort to lower drug prices for Americans. But he said TrumpRx doesn’t serve as a “one-stop shop” for consumers who want to compare drug prices and secure the lowest costs, describing the system as more of a “catalog of coupons from existing programs from drug companies.”

Wright also said he’d like to see TrumpRx offer a broader range of drugs, including those used to treat cancer and other diseases (see below for a list of all drug discounts available through TrumpRx.) 

The White House told CBS News that such discounts only exist because the Trump administration negotiated so-called “most-favored-nation” agreements with pharmaceutical firms to lower prices. Under that policy, drugmakers must sell meds to U.S. customers at the same prices available in other countries, including those with lower drug costs. 

TrumpRx is also focused on offering the lowest prices on branded products, the White House noted, acknowledging that more affordable generic versions of the drugs may be available elsewhere. 

Who is TrumpRx for?

A drawback of TrumpRx is that discounts are available only to patients who buy drugs in cash, Wright said. That means people must pay for prescriptions out of pocket and can’t use their health insurance, while those expenses will not count toward meeting a consumer’s health plan deductible. 

“It is focused pretty narrowly on people who are uninsured and are buying prescription drugs with cash rather than through a health plan,” Wright told CBS News.

When TrumpRx launched on Feb. 5, the site listed more than 40 brand-name drugs, with the Trump administration saying that more discounted medications will be added over time. 

Merith Basey, CEO of Patients For Affordable Drugs Now (P4ADNow), a national patient organization that works to lower drug prices, said the coupons TrumpRx offers are not unique to the platform, noting that similar discounts are already available in the marketplace.

To assess the savings available through TrumpRx, the group compared the service with what consumers can find for the same drugs via GoodRx, a Santa Monica, Calif., company that offers discounted meds. TrumpRx’s pricing was superior for only eight drugs, P4ADNow found, as follows:

  • Bevespi (chronic bronchitis) — 89% discount through TrumpRx
  • Cetrotide (fertility)  — 93% discount through TrumpRx
  • Farxiga (Type 2 Diabetes) — 52% discount through TrumpRx
  • Genotropin (human growth hormone) — 60% discount through TrumpRx
  • Insulin Lispro (blood sugar control) — 65% discount through TrumpRx
  • Ovidrel (fertility) — 67% discount through TrumpRx
  • Xigduo XR (Type 2 Diabetes) — 70% discount through TrumpRx
  • Zepbound (weight loss) — 72% discount through TrumpRx

GoodRx offered equally steep discounts on 33 of the drugs listed on TrumpRx, while cheaper generic alternatives were available for 15 TrumpRx medications, according to the group’s analysis. 

For example, Colestid, a drug that lowers cholesterol for people at risk of heart disease, costs $67.20 if purchased through TrumpRx, while a generic version of the drug costs $21.70.

Most insurers don’t cover weight-loss drugs like Ozempic and Wegovy. TrumpRx and GoodRx both offer Ozempic for $199 for a 0.25 milligram pen, which has a list price of over $1,000. 

The same is typically true of fertility drugs, including Gonal-F, which costs $252 with a TrumpRx or GoodRx coupon and which has a list price of nearly $1,200.

Drug discounts available through TrumpRx

For now, TrumpRx offers discounts on a total of 43 drugs, as follows:

  • Abrilada pen (autoimmune) — TrumpRx price: $207.60
  • Airsupra (respiratory) — TrumpRx price: $201
  • Azulfidine Tabs (rheumatology) — TrumpRx price: $99.60
  • Azulfidine En Tabs (rheumatology) — TrumpRx price: $130.80
  • Bevespi (respiratory) — TrumpRx price: $51
  • Cetrotide (IVF) — TrumpRx price: $22.50
  • Chantix (smoking cessation) — TrumpRx price: $106.20
  • Cleocin (antibiotic) — TrumpRx price: $94.35
  • Colestid (cholesterol) — TrumpRx price: $127.91
  • Cortef (inflammation) — TrumpRx price: $45
  • Cytomel (thyroid) — TrumpRx price: $6
  • Diflucan (antifungal) — TrumpRx price: $14.06
  • Duavee (women’s health) — TrumpRx price: $30.30
  • Estring (women’s health) — TrumpRx price: $249
  • Eucrisa (dermatologic) — TrumpRx price: $158.48
  • Farxiga (diabetes, cardiovascular) — TrumpRx price: $181.59
  • Genotropin (human growth hormone) — TrumpRx price: $89.67
  • Gonal F (fertility) — TrumpRx price: $168
  • Insulin Lispro (high blood sugar) — TrumpRx price: $25
  • Levoxyl (hypothyroidism) — TrumpRx price: $35.10
  • Lopid (cholesterol) —TrumpRx price: $39.60
  • Medrol (inflammation) —TrumpRx price: $3.15
  • Ngenla (human growth hormone) — TrumpRx price: $2,217
  • Nicotrol (smoking cessation) — TrumpRx price: $271.16
  • Ovidrel (fertility) —TrumpRx price: $84
  • Ozempic Pen (diabetes, weight loss) — TrumpRx price: $199
  • Premarin (women’s health) — TrumpRx price: $99
  • Premarin Vaginal Cream (women’s health) — TrumpRx price: $236.65
  • Prempro (women’s health) — TrumpRx price: $98.84
  • Pristiq (antidepressant) — TrumpRx price: $200.10 
  • Protonix (heartburn) — TrumpRx price: $200.10
  • Tikosyn (cardiovascular) — TrumpRx price: $336
  • Toviaz (bladder control) — TrumpRx price: $43.50
  • Vfend (antifungal) — TrumpRx price: $306.98
  • Viracept (antiviral) — TrumpRx price: $607.20
  • Wegovy (weight loss) — Pen TrumpRx price: $199
  • Wegovy Pill (weight loss) — TrumpRx price: $149
  • Xeljanz (rheumatology) — TrumpRx price: $1,518
  • Xigduo Xr (diabetes) — TrumpRx price: $181.59
  • Zarontin (anticonvulsant) — TrumpRx price: $71.10
  • Zavzpret (migraine treatment) — TrumpRx price: $594.84
  • Zepbound (weight loss, sleep apnea) — TrumpRx price $299
  • Zyvox (antibiotic) — TrumpRx price: $122.74

Access Denied

0
Access Denied


Access Denied

You don’t have permission to access “http://food.ndtv.com/food-drinks/ya-allah-chala-de-hotel-in-delhi-serves-up-the-best-butter-chicken-in-world-swears-saqib-saleem-11000546” on this server.

Reference #18.dd711102.1771026624.124ce84f

https://errors.edgesuite.net/18.dd711102.1771026624.124ce84f

Valentine’s Day 2026: Romantic Home Decor Ideas To Surprise Your Partner

0
Valentine’s Day 2026: Romantic Home Decor Ideas To Surprise Your Partner

Last Updated:

Valentine’s Day 2026, February 14, 2026: Transforming your home into a romantic sanctuary for Valentine’s Day 2026 creates an intimate atmosphere that restaurants cannot replicate.

Next Photogallery

T20 World Cup: USA survive knockout threat with victory over Netherlands

0
T20 World Cup: USA survive knockout threat with victory over Netherlands

Netherlands’ Zach Lion-Cachet is clean bowled during the 2026 ICC Men’s T20 Cricket World Cup group stage match between Netherlands and USA at MA Chidambaram Stadium in Chennai on February 13, 2026. — AFP

The United States of America (USA) kept their ICC Men’s T20 World Cup 2026 campaign alive with a 93-run victory over the Netherlands in the tournament’s 21st group stage match at MA Chidambaram Stadium, Chennai, on Friday.


This is a developing story and is being updated with more details.

“Sinners” cinematographer opens up about career journey amid historic Oscar nomination

0
"Sinners" cinematographer opens up about career journey amid historic Oscar nomination

“Sinners” cinematographer Autumn Durald Arkapaw says she doesn’t want the audience to notice her work because “you wanna make it so good it feels like a dream.” The Oscar nominee is the first woman of color nominated in the cinematography category and only the fourth woman ever. It’s the only Oscars category never won by a woman. She talks about her career journey to this historic moment.

Stocks dip further on disappointing results | The Express Tribune

0
photo file


KARACHI:

Pakistan’s stock market extended its bearish spell on Friday as the benchmark KSE-100 index fell over 900 points amid disappointing corporate earnings and cautious investor sentiment during the ongoing result season.

Market activity remained subdued, while foreign investors offloaded shares worth Rs4.2 billion, adding to pressure on equities despite a late-session recovery that helped the index hold above key support levels. Major drags on the index included heavyweight stocks from cement, banking, fertiliser, technology, and oil and gas sectors, with Lucky Cement, UBL, OGDC, Systems Ltd, Engro Fertilisers and Engro Holdings collectively erasing hundreds of points.

Analysts attributed the market weakness to earnings falling short of expectations, though the index managed to sustain above crucial technical levels, keeping investors focused on upcoming developments and the 180,000-point mark as a decisive support-resistance zone.

At the close of trading, the KSE-100 index posted a decline of 908.92 points, or 0.50%, and settled at 179,603.73.

Arif Habib Limited (AHL) noted that the KSE-100 recorded its third consecutive weekly decline, losing 2.46% week-on-week. On Friday, the market breadth remained negative with 43 stocks advancing while 56 declined. Key positive contributors included Habib Metropolitan Bank (+4.68%), NBP (+1.72%) and K-Electric (+4.02%), whereas Lucky Cement (-2.54%), UBL (-1%), and OGDC (-1.91%) weighed on the index.

Among corporate developments, Pakistan Petroleum announced its 2QFY26 financial results, posting earnings per share of Rs7.46, down 26% year-on-year, along with a dividend of Rs2 per share. The earnings decline was attributed primarily to a 13.2% YoY drop in oil prices, higher operating expenses, reduced other income, and an elevated effective tax rate.

On the macro front, Pakistan attracted its largest monthly net foreign inflows into sovereign bonds since June 2024, with January inflows reaching $176 million compared to net withdrawals of $50 million in the same month of last year. Looking ahead, AHL highlighted an important week for the KSE-100, with the 180,000 level expected to determine whether it acts as a key support or resistance zone.

Topline’s market review noted that continuing its negative momentum, the KSE-100 largely traded in the negative zone to settle at 179,604 (down by 0.50%). The negativity can be attributed to the results season, where corporate earnings have fallen short of investors’ expectations.

The top negative contribution to the index came from Lucky Cement, UBL, OGDC, Systems Ltd, Engro Fertilisers and Engro Holdings, as they cumulatively erased 685 points. Traded value-wise, OGDC (Rs4.1 billion), Pakistan Petroleum (Rs3 billion), NBP (Rs2.7 billion), Lucky Cement (Rs1.87 billion), Engro Holdings (Rs1.7 billion) and Systems Ltd (Rs1.55 billion) dominated the activity, Topline said.

Muhammad Hasan Ather of JS Global said that the KSE-100 declined by 909 points, but managed to hold above key support levels. The market witnessed a late-session recovery amid the broader bearish trend, sustaining above the 178,500 support level. Major laggards included cement, fertiliser, oil & gas, and banking stocks. “We believe that any meaningful developments regarding the Reko Diq project will remain pivotal in shaping market sentiment going forward,” he said.

Nasheed Malik, Head of Research at Growth Securities, said foreign corporates led broad-based selling worth Rs4.2 billion across key sectors, reflecting short-term concerns tied to geopolitical and security uncertainties, including developments around Reko Diq and Balochistan.

However, he noted that strong domestic liquidity and unallocated institutional funds could support the market once conditions stabilise, with foreign investment likely to return over the longer term.

Overall trading volume was recorded at 709 million shares compared with the previous session’s tally of 874 million. The value of shares traded during the day was Rs38.9 billion.

Shares of 481 companies were traded. Of these, 194 stocks closed higher, 231 fell, and 56 remained unchanged.

K-Electric was the volume leader with trading in 131.1 million shares, gaining Rs0.33 to close at Rs8.55. It was followed by Pakistan International Bulk Terminal with 34.7 million shares, gaining Rs0.14 to close at Rs19.53, and WorldCall Telecom with 33.8 million shares, losing Rs0.02 to close at Rs1.63.